(VIANEWS) – Shares of ERYTECH PHARMA (CAC 40: ERYP.PA) jumped by a staggering 30.73% in 21 sessions from €0.59 to €0.77 at 19:54 EST on Friday, after three consecutive sessions in a row of losses. CAC 40 is sliding 1.78% to €7,187.27, following the last session’s upward trend.
ERYTECH PHARMA’s last close was €0.82, 63.52% below its 52-week high of €2.26.
About ERYTECH PHARMA
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
Earnings Per Share
As for profitability, ERYTECH PHARMA has a trailing twelve months EPS of €-0.93.
More news about ERYTECH PHARMA (ERYP.PA).
